← back to search

Diana J. Azzam

Florida International University · US
Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Cells and Metastasis, Mechanisms of cancer metastasis, Cancer Genomics and Diagnostics, and Protein Degradation and Inhibitors.
h-index
16
citations
2,187
works
113
NIH funding
primary concept
email

Recent publications

Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers
Nature Medicine 2024cited by 60position: lastdoi
DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
Clinical Cancer Research 2022cited by 70position: middledoi
Clinical Utility of Functional Precision Medicine in the Management of Recurrent/Relapsed Childhood Rhabdomyosarcoma
JCO Precision Oncology 2021cited by 11position: lastdoi
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells
Clinical Cancer Research 2018cited by 70position: middledoi
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer
Oncogene 2016cited by 186position: middledoi
Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b–Mediated Malignant Progression
Cancer Research 2016cited by 184position: middledoi
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
Cell 2014cited by 794position: middledoi
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
Oncogene 2014cited by 262position: middledoi
Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures
Breast Cancer Research and Treatment 2014cited by 38position: middledoi
Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ‐secretase inhibitor drug responses
EMBO Molecular Medicine 2013cited by 64position: firstdoi
Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models <i>In Vitro</i> and <i>In Vivo</i>
Clinical Cancer Research 2012cited by 62position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Joyce M. Slingerland · University of Miami8 papers (2012–2022)Dekuang Zhao · Tongji University4 papers (2013–2018)Dorraya El‐Ashry · University of Minnesota4 papers (2013–2016)Tan A. Ince · NewYork–Presbyterian Brooklyn Methodist Hospital4 papers (2012–2018)Katherine Drews‐Elger · University of Miami4 papers (2013–2016)Manuel Picon‐Ruiz · University of Miami3 papers (2013–2016)Candace A. Gilbert · University of Massachusetts Chan Medical School3 papers (2012–2014)Andy J. Minn · Parker Hannifin (Germany)2 papers (2013–2014) · 2 papers (2021–2024)Kibeom Jang · University of Miami2 papers (2016–2018)Ziad Khatib · Florida International University2 papers (2021–2024)Tomás R. Guilarte · Columbia University2 papers (2021–2024)Chendong Pan · Cornell University2 papers (2014–2016)Gordon B. Mills · Massachusetts General Hospital2 papers (2012–2018)Arlet Acanda de la Rocha · Florida International University2 papers (2021–2024)Jun Sun · University of Miami2 papers (2012–2018)Maggie Fader · Florida International University2 papers (2021–2024)Ebony Coats · Florida International University2 papers (2021–2024)Cristina M. Andrade-Feraud · Florida International University2 papers (2021–2024)Minsoon Kim · University of Miami2 papers (2016–2018)